Extended intervals and extra doses of the AstraZeneca vaccine are associated with increased immunogenicity.

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) – The Lancet

Invited commentary: Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine

Commentaries on Twitter

(thread – click for more)

Substudy suggests extended interval (up to 45 wks) before 2nd dose of ChAdOx1 nCoV-19 leads to increased antibody titres, offering more flexibility in vaccine schedules.

Extended interval before 3rd dose resulted in further increase in immune responses. https://t.co/J3xOwSSYMN pic.twitter.com/8GotDI4ctS

— The Lancet (@TheLancet) September 2, 2021

(thread – click for more)

New @TheLancet
The heightened immune response to longer spacing @AstraZeneca 1st -> 2nd vaccine doses and the response 3rd booster dose, with high neutralizing antibodies and T cellshttps://t.co/A2UcPVIFYP pic.twitter.com/zfYaW0T8Yf

— Eric Topol (@EricTopol) September 1, 2021